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Abstract
Peptide inhibitors derived from HIV-gp41 envelope protein play a pivotal role in deciphering the molecular mechanism of
HIV-cell fusion. According to accepted models, N-heptad repeat (NHR) peptides can bind two targets in an intermediate
fusion conformation, thereby inhibiting progression of the fusion process. In both cases the orientation towards the
endogenous intermediate conformation should be important. To test this, we anchored NHR to the cell membrane by
conjugating fatty acids with increasing lengths to the N- or C-terminus of N36, as well as to two known N36 mutants; one
that cannot bind C-heptad repeat (CHR) but can bind NHR (N36 MUTe,g), and the second cannot bind to either NHR or CHR
(N36 MUTa,d). Importantly, the IC50 increased up to 100-fold in a lipopeptide-dependent manner. However, no preferred
directionality was observed for the wild type derived lipopeptides, suggesting a planar orientation of the peptides as well as
the endogenous NHR region on the cell membrane. Furthermore, based on: (i) specialized analysis of the inhibition curves,
(ii) the finding that N36 conjugates reside more on the target cells that occupy the receptors, and (iii) the finding that N36
MUTe,g acts as a monomer both in its soluble form and when anchored to the cell membrane, we suggest that anchoring
N36 to the cell changes the inhibitory mode from a trimer which can target both the endogenous NHR and CHR regions, to
mainly monomeric lipopetides that target primarily the internal NHR. Besides shedding light on the mode of action of HIV-
cell fusion, the similarity between functional regions in the envelopes of other viruses suggests a new approach for
developing potent HIV-1 inhibitors.
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Introduction
HIV-1, like other enveloped viruses, utilizes a protein embedded
in its membrane, termed envelope glycoprotein
1(ENV), to
facilitate the fusion process [1,2,3]. The ENV is organized as
trimers on the membrane of the virus, and is composed of two
non-covalently associated subunits. The surface subunit (SU),
gp120, mediates host tropism [4,5]), whereas the transmembrane
subunit (TM), gp41, is responsible for the actual fusion event
(reviewed in [6]). The extracellular part of gp41 is composed of
several functional regions including the fusion peptide (FP), the N-
terminal heptad repeat (NHR), the C-terminal heptad repeat
(CHR), and the pre-transmembrane (PTM) domain.
The ability of the virus to fuse its own membrane with that of
the hosting cell is due to conversion among three identified ENV
conformations. Initially, the envelope subunits are in a metastable
native conformation [7], in which gp41 is considered to be
sequestered by gp120. Binding of gp120 to specific cell receptors
involves conformational changes in both subunits, resulting in the
pre-fusion conformation [7,8] in which gp41 is exposed and
extended, leading to insertion of the FP into the host cell
membrane [9]. Additional conformational changes produce the
post fusion conformation [10,11], where a trimeric central coiled-
coil is created by three NHR regions. These three CHR regions
are packed in an anti-parallel manner into conserved hydrophobic
grooves exposed on the surface of the central NHR coiled-coil. A
complex representing this structure has been resolved by X-ray
crystallography [12,13], and is designated as the ‘‘six helix bundle’’
(SHB) or ‘‘core’’ structure. Similar bundles are created in
intracellular vesicle fusion by SNARE proteins demonstrating a
common mechanism in diverse systems [14,15].
Inhibition of HIV-1-mediated fusion has been demonstrated by
several N- or C-peptides: peptides that originate from the
endogenous NHR or the CHR sequence of gp41, respectively
[7,16]. The common model is that C-peptides bind the
endogenous NHR region in the pre-fusion conformation, thereby
blocking core formation [17,18,19]. N-peptides, on the other
hand, have two distinct modes of inhibitory action: binding of the
endogenous CHR region in the pre-fusion conformation, thereby
blocking core formation, and binding the endogenous NHR
region to disrupt the creation of the internal NHR coiled-coil [20].
Previously it has been demonstrated that anchoring of inhibitory,
expressed CHR peptides, to the membrane of cells can increase
their inhibitory activity, as well as aid in deciphering the
intermediate steps in the viruses’ fusion [9,21]. We have
demonstrated earlier that conjugation of fatty acids to peptides
PLoS Pathogens | www.plospathogens.org 1 July 2009 | Volume 5 | Issue 7 | e1000509can sufficiently anchor a short CHR-peptide to the membrane of
cells, dramatically increase its inhibitory activity, and reveal the
boundary of the core structure in a dynamic fusion process [22].
The observation that the increase in the inhibitory activity was
significantly more pronounced when the fatty acid was attached to
the C-terminus compared with the N-terminus supported a
preferred orientation of the CHR peptide towards the endogenous
pre-hairpin conformation. Here we address the role of the
orientation of membrane bound NHR peptides during the
ongoing fusion event and its implication on the understanding of
the molecular mechanism of gp41 fusion.
Materials and Methods
Materials
Fmoc amino acids including lysine with a 4-Methyltrityl (MTT)
side chain protecting group and Fmoc Rink Amide MBHA resin
were purchased from Nova-biochem AG (Laufelfinger, Switzer-
land). Other peptide synthesis reagents, fatty acids octanoic acid
(C8), dodecanoic acid (C12), and hexadecanoic acid (C16), LPC
(lysophosphatidylcholine), and PBS were purchased from Sigma
Chemical Co. (Israel). DiD (DiIC18(5) or 1,19-dioctadecyl-
3,3,39,39,-tetramethylindodicarbocyanine, 4-chlorobenzenesulfo-
nate salt), DiI (1,19- dioctadecyl-3,3,39,39,0 tetramethylinocarbo-
cyanine perchlorate) lipophilic fluorescent probes and NBD-F (4-
fluoro-7-nitrobenzofurazan) were obtained from Biotium (Califor-
nia, USA). Buffers were prepared in double-distilled water.
Cell Lines and Reagents
Cell culture reagents and media were purchased from Biological
Industries Israel (Beit Haemek LTD). All cell lines were obtained
through the NIH AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH. Jurkat E6-1 cells were
from Dr. Arthur Weiss [23], Jurkat HXBc2 (4) cells expressing
HIV-1 HXBc2 Rev and ENV proteins were from Dr. Joseph
Sodroski [24], TZM-bl cells were from Dr.John C. Kappes, Dr.
Xiaoyun Wu, and Tranzyme Inc [25,26], and HL2/3 cells were
from Dr. Barbara K. Felber and Dr. George N. Pavlakis [27].
Cells were cultured every 3 to 4 days, and maintained in RPMI-
1640 or DMEM supplemented with the appropriate antibiotics at
37uC with 5% CO2 in a humidified incubator. For ENV
expression, Jurkat HXBc2 (4) cells were transferred to medium
without tetracycline three days prior to the experiments.
Peptide Synthesis, Fatty Acid Conjugation, and
Fluorescent Labeling
GCN4 trimer, C34, and N36 were synthesized on Rink Amide
4-Methylbenzhydrylamine (MBHA) resin by using the Fmoc
strategy as previously described [28]. C-terminally conjugated N36
peptides contain a lysine residue at their C-terminus with an MTT
side chain protecting group, enabling the conjugation of a fatty
acid that required a special deprotection step under mild acidic
conditions (261 min. of 5% TFA (trifluoro acetic acid) in dichloro
methan (DCM) and 30 min. of 1% TFA in DCM). Conjugation of
a fatty acid to the N-terminus was performed using standard Fmoc
chemistry. Addition of the NBD (emission-530 excitation-467)
fluorescent probe to the N- or C-terminus of selected peptides was
performed using 3 equivalents of NBD-F in a 2% diisopropylamin
(DIEA) solution in DMF for one hour. All peptides were cleaved
from the resin by a TFA: DDW: TES (93.1:4.9:2 (v/v)) mixture,
and purified by reverse phase high performance liquid chroma-
tography (RP-HPLC) to .95% homogeneity. The molecular
weight of the peptides was confirmed by platform LCA
electrospray mass spectrometry.
Cell-Cell Fusion Inhibition Assay
The protocol utilizing Jurkat E6-1 and Jurkat HXBc2 cells for a
cell-cell fusion assay was previously described [29]. In short, Jurkat
E6-1 and Jurkat HXBc2 cells were labeled with DiI and DiD
lipophilic fluorescent probes, respectively. The two cell popula-
tions were co-incubated, in a ratio of 1:1, for 6 h in the presence of
eight different concentrations of the inhibitory peptides. Prior to
measurements the cells were washed, spinned, dissolved in PBS,
and put on ice. Cells co-incubated without the presence of peptides
served as an optimal fusion reference. Unlabeled cells that were
handled similarly served as an intrinsic fluorescence control. Cells
labeled separately with DiI or DiD were used to adjust the optimal
separation of fluorescent signals. Jurkat HXBc2 cells labeled with
DiI were co-incubated with Jurkat HXBc2 cells labeled with DiD
for a fusion background that was subtracted from the measure-
ments of the experiment. The following alterations were applied to
the original protocol: (i) 5 mL of a 1 mg/mL DiI or DiD solution in
dimethylsulfoxide (DMSO) was added to 1 mL of 4610
6 cells/mL
Jurkat E6-1 or Jurkat HXBc2 cells, respectively. (ii) For each data
point 150,000 events were collected. Measurements were per-
formed on a FACSort machine, upgraded to a FACSCalibur cell
analyzer (Becton Dickinson). Fitting of the data points was







In this equation B is the maximum value, therefore it equals 100%
fusion, A is the IC50 value, and c represents Hill’s coefficient, in this
particular case: the inhibitory oligomeric state of the peptide. For
the fitting, we uploaded the X and Y values of the raw data (after
subtracting the background) into a nonlinear least squares
regression (curve fitter) program that provided the IC50 value (A
of the equation), as well as the c value.
Triple Staining Flow Cytometry Fusion Assay
For triple staining, the same cell-cell fusion inhibition assay
experiment as above was performed in the presence of NBD-
labeled peptides. Cells labeled separately with DiI or DiD, and
Author Summary
Acquired immunodeficiency syndrome (AIDS) is a major
global health problem, and its causative agent, human
immunodeficiency virus (HIV), is extensively studied. To
start an infectious cycle HIV must fuse its membrane with
that of its host cell. A specific protein on the virus surface
facilitates this process by undergoing major conforma-
tional changes. Several virus-cell fusion inhibitors target
transiently exposed regions during the conformational
changes, thereby preventing progression of the fusion
process. Here, we focused on a specific fusion inhibitor
peptide having two distinct binding sites and modes of
inhibitions. By simple chemical modifications we demon-
strate a shift between these two modes of inhibition. Most
importantly, we reveal novel details regarding the
conformational changes during the fusion process. Fur-
thermore, the chemical modifications extremely enhanced
the fusion inhibitory potency of the peptide. Lastly, since
the fusion process of HIV shares common features with
diverse biological processes, our results might contribute
to their research and therapeutic efforts as well.
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used to compensate for the optimal separation of the three
fluorescent signals. For each data point 500,000 events were
collected. The eight different possible combinations (triple, NBD,
DiI, DiD, NBD+DiI, NBD+DiD, DiI+DiD, no label) were defined
in the analysis software and the percentage of each one was
calculated. The percentage of NBD labeling (peptide) on all cell
types in relation to all available labeled cells in the system was





Triplez NBDzDil ðÞ z NBDzDiD ðÞ |100
TriplezDiDzDilz DiDzDil ðÞ z NBDzDiD ðÞ z NBDzDil ðÞ
Additionally, the percentage of NBD labeling (peptide) in cells
labeled with DiD (effector) or DiI (target) cells was further
calculated. Analysis of the data enabled us to examine the relative
binding of labeled peptides to different cell populations, namely,
target or effector cells.
NBD on effector cells
All effector cells
~
Triplez NBDzDiD ðÞ |100
Triplez NBDzDiD ðÞ z DilzDiD ðÞ zDiD
NBD on target cells
All target cells
~
Triplez NBDzDil ðÞ |100
Triplez NBDzDil ðÞ z DilzDiD ðÞ zDil
Circular Dichroism (CD) Spectroscopy
CD measurements were performed on an Aviv 202 spectropo-
larimeter. The spectra were scanned using a thermostatic quartz
cuvette with a path length of 1 mm. Wavelength scans were
performed at 25uC, the average recording time was 15 sec., in
1 nm steps, the wavelength range was 190–260 nm. Peptides were
scanned at a concentration of 10 mM in HEPES buffer (5 mM,
pH 7.4) and in a membrane mimetic environment of 1% LPC in
double distilled H2O.
Results
Anchoring of N36 to the Membrane Increases Its
Inhibitory Activity
To scrutinize the effect of anchoring N36 to the membrane, we
conjugated octanoic, dodecanoic, and palmitic acids to the N-
terminus of N36 (Table 1). The resulting peptides C8-N36, C12-
N36, and C16-N36 were examined in a cell-cell fusion inhibition
assay and the results are shown in Figure 1. A correlation was
observed between the length of the conjugated fatty acid and the
inhibitory activity of the N- conjugated N36 peptides. N36, C8-
N36, C12-N36, and C16-N36 exhibited IC50 values of 4886119,
222656, 190621, and 72627 nM, respectively. Interestingly,
AcN36 was not active up to 2000 nM; therefore we refer to it as
inactive. This correlates with previous studies demonstrating an
IC50 of 1600062000 nM and 584646 nM for the acetylated and
non-acetylated forms of N36, respectively [20,30]. Overall, our
data reveal that the anchoring of N36 to the membrane
significantly increases its inhibitory activity.
The Orientation of Anchored N36 toward the
Endogenous CHR Region Is Not Crucial
To examine the importance of the proper orientation of the
N36 peptide in relation to the pre-fusion conformation, we also
conjugated octanoic, dodecanoic, and palmitic acids to the C-
terminus of modified N36, termed N36M (Table 1). The parental
peptide and the resulting fatty acid-conjugated peptides N36M,
N36M-C8, N36M-C12, and N36M-C16 (Table 1) were examined
in a cell-cell fusion inhibition assay and the results are presented in
Figure 1. Likewise, a correlation was observed between the length
of the conjugated fatty acid and the inhibitory activity of the C-
conjugated N36 peptides. N36M, N36M-C8, N36M-C12, and
N36M-C16 exhibited IC50 values of 531648, 354625, 241689,
and 159647 nM, respectively. Since acetylating N36 abrogates its
activity we added an acetyl group to N36M-C12 and N36M-C16
resulting in AcN36M-C12 and AcN36M-C16. Both lipopeptides
were examined in a cell-cell fusion inhibition assay and exhibited
IC50 values of 226638, and 125651 nM, respectively. Since these
values are similar to those of N36M-C12 and N36M-C16 we can
conclude that the charge in their N-terminus does not influence
their inhibitory ability, contrary to N36.
Interestingly, there was only a slight difference between the
activities of N- and C-terminally conjugated peptides having the
Figure 1. Cell-cell fusion inhibition assay for the N36 peptide and its fatty acid conjugates. Fusion inhibition (IC50 values) induced by the
peptides. For each peptide at least four independent experiments were performed and were included in the calculation of the standard deviation.
doi:10.1371/journal.ppat.1000509.g001
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the C-helix peptide, in which there was a marked difference (,30-
fold) between them [22]. Thus, we can conclude that the length of
the fatty acid is important, and it is correlated to the inhibitory
activity, whereas primarily, the orientation of the peptides is not
critical for their activity pattern.
Inhibitory Curves Analysis Suggest a Different Mode of
Inhibition for the Peptides
Representative experiments showing the inhibitory activity
curves of N36 and its N-terminally fatty acid-conjugated analogs
is presented in Figure 2A. It reveals different shapes of the
inhibition curves for the different peptides shifted from sigmoid
through a median shape to hyperbolic. A sigmoid shape can be
explained by the tendency of N36 to oligomerize. Therefore, we
speculated that the different binding curves might be attributed to
a different inhibitory oligomeric state of the peptides. Conse-
quently, for optimal fitting, we employed an equation that contains
a cooperativity parameter, indicative in this case, to the inhibitory
oligomeric state of the peptide. Therefore, after a fit is achieved,
the c value represents the oligomeric state of the peptide. The
values of the oligomerization parameters (averaged from at least
four independent experiments) for the different peptides are
presented in Figure 2B. The c values for the N- conjugated N36
peptides, namely: N36, C8-N36, C12-N36, and C16-N36 are
2.67, 2.61, 1.77, and 1.47 respectively. The c values for the C-
conjugated N36 peptides, namely: N36M, N36M-C8, N36M-C12,
and N36M-C16 are 3.19, 2.82, 1.67, and 1.19 respectively. The c
parameter for the original peptide (N36 or N36M) was compared
to the c parameter of its longest fatty acid conjugate (C16-N36 or
N36M-C16) by the nonparametric Mann-Whitney test, the two
sided significance was p=0.016, demonstrating statistical signifi-
cance for these results. These data reveal an interesting shift in the
oligomerization tendency. It suggests that for the native peptides,
N36, and N36M, the tendency is for the trimeric form. The longer
the fatty acid the lower is the oligomerization value until it almost
reaches a monomer with the C16-N36, and N36M-C16 peptides.
Relative Binding of Labeled Peptides to the Membrane of
Cells
We tested whether the attachment of the fatty acids to the
peptides allowed their anchoring to the cell membrane by utilizing a
triple staining flow cytometry assay that incorporates fluorescently
labeled target cells, effector cells, and inhibitory peptides [22]. This
assay allowed the determination of the IC50 of the peptides, as well
as monitoring the percentage of cells labeled with the different
peptides (Table 2). We analyzed the most and least active peptides,
namely, NBDN36 (parallel in its inhibitory activity to AcN36),
NBDN36M-C16, and C16-N36NBD (Figure 3). The NBDGCN4
peptide served as a negative control for a non-binding peptide,
whereas, C16-NBDGCN4 served as a positive control for a strongly
binding peptide. As expected, both are not inhibitors (data not
shown). The data reveal a direct correlation between the activity of
the N-helix peptides and their global binding to the cells.
Structure of the Peptides in Solution and in a Membrane
Mimetic Environment Alone and in Combination with the
C-Helix C34
We determined the secondary structure of the most active and
inactive peptides in solution to find out whether this feature
correlates with their activity pattern. N36 and N36M exhibited a-
helical structures in solution, whereas the structure of AcN36,
C16-N36, and N36M-C16 was undefined (Figure 4). The
peptides’ ability to create a core structure with C34 in solution
was also monitored. The CD signal of each peptide was measured
and this signal was added to the signal of C34. This calculated
combined signal would represent the signal in the case that the
peptides do not interact with each other. This signal was compared
to the actual signal monitored upon co-incubation of the two
peptides together. If the two peptides interact one with each other,
we would expect to see a difference between the two signals.
AcN36, in contrary to the results presented in a previous study
[31], and C16-N36 were unable to create a core structure,
whereas N36 and N36M-C16 did interact with C34 (Figure 4)
[32,33]. Note that Chan et al have used the C-34 and the N-36
peptides both in their acetylated forms and obtained a stable core.
Here we obtained a stable core with both peptides in their non-
acetylated forms, but we could not get a stable core with one
acetylated and one non-acetylated peptides, the reason for which is
not clear. The structure of the peptides alone, and their ability to
create a core structure with C34 was also measured in a
membrane mimetic environment (Figure 4). Under these condi-
tions, all the peptides exhibited a-helical structures. However, with
all peptides, the non-interactive signal overlapped the experimen-
tal signal. In this case, the overlap does not necessarily mean that
there is no creation of the core structure. Since all peptides have
strong helical signals by themselves they could create a core
structure without an observed change in the secondary structure.
Overall, these data demonstrate that the structure of the peptides
and their ability or inability to create a core structure with C34 (in
Table 1. Sequences, designations, and IC50 values of the peptides and their lipophilic conjugates.
Designation X Peptide sequence ZI C 50(nM)
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for their activity pattern.
Utilizing Known N36 Mutants to Explore the Inhibitory
Mechanism
In order to investigate further the mechanism of inhibition we
utilized known N36 mutants [20] (see Table 3 for sequences). The
first was N36 MUTe,g which contains mutations in its e and g
positions. These mutations preserve its ability to self-assemble into
trimers, but it cannot interact with the CHR. The second mutant
was N36 MUTa,d which contains mutations in it’s a and d
positions knocking out its ability to interact with itself, thus leading
to inability to create the internal coiled-coil. These mutants
demonstrated that the NHR can inhibit by preventing the
Figure 2. The inhibitory oligomeric state of the peptides. (A) Fusion inhibition curves of the N-terminally conjugated peptides (other data not
shown). N36, C8-N36, C12-N36, and C16-N36 are represented by closed squares, diamonds, circles, and triangles, respectively, and the fitted curves
are represented by continuous lines. (B) The inhibitory oligomeric state of the peptides. The Hill’s coefficient parameter for the different peptides is
presented. For each peptide at least four independent experiments were performed and were included in the calculation of the standard deviation.
doi:10.1371/journal.ppat.1000509.g002
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dimer), or by binding to the CHR domain to prevent SHB
formation (probably as a trimer). We conjugated a palmitic acid to
the N or C- terminus of both of them (Table 3) and determined
their IC50 inhibitory values. As expected, N36 MUTa,d was
inactive alone and when conjugated to palmitic acid, because it
could not bind itself, as well as CHR, therefore both modes of
inhibitions could not take place. Strikingly however, the
attachment of palmitic acid to N36 MUTe,g caused an increase
of 7-fold to 100-fold in its IC50 compared to the soluble peptide,
depending on the directionality of the conjugation. N36 MUTe,g,
C16-N36 MUTe,g, and N36 MUTe,g-C16 exhibited IC50 values of
936636, 16264, and 8.864 nM, respectively (Figure 5). Such
preference was not observed with the wild type N36 which
preserve binding to the CHR region. The data analysis suggested a
trimeric and monomeric modes of inhibition for the wild type N36
and its palmitic acid conjugates, respectively (Figure 2B). Here,
N36 MUTe,g, C16-N36 MUTe,g, and N36 MUTe,g present
oligomerization parameters values of 1.4, 0.77, and 1.4 respec-
tively (Figure 5B), suggesting primarily a monomeric mode of
inhibition. The c parameter of N36 MUTe,g, C16- N36 MUTe,g,
and N36 MUTe,g-C16 was compared to the c parameters of N36,
N36M, C16-N36, N36M-C16, and to themselves by the
nonparametric Mann-Whitney test. Even though our sample size
is small, out of 14 comparisons only one did not obey our
predictions.
Comparing Fusion Inhibition Results to Those Obtained
with a Reporter Gene Assay
Our cell-cell fusion assay is based on lipophilic fluorescent
probes. Therefore, there is a risk that the inhibitory results that we
obtained are due to hemifusion. In order to exclude this possibility,
we performed a reporter gene cell-cell fusion assay for represen-
tative peptides as a proof of concept. The gene reporter assay is
based on activation of HIV long terminal repeat-driven luciferase
cassette in TZM-bl (target) cells by HIV-1 tat from the HL2/3
(effector) cells. The peptides that we examined were: N36, N36M,
N36M-C16, and N36 MUTe,g-C16. Their original IC50 values
(nM) were: 488, 531, 159, and 8.8 respectively, in comparison to:
472, 333, 128, and 8 respectively, in the gene reporter assay
experiment. Since the values were comparable we conclude that
the inhibitory results obtained with our cell-cell fusion assay
represent full fusion and not hemifusion.
The Relative Binding of Labeled Peptides to the
Membrane of Specific Cell Populations
To examine whether the peptides have an enhanced tendency
to bind the cells with the receptors (target cells), or those with the
ENV glycoprotein (effector cells), in a dynamic fusion process, we
employed a triple staining assay. Fluorescently labeled peptides
were incubated with differently labeled effector and target cells,
exactly according to the protocol of the cell-cell fusion assay. The
Figure 3. Relative binding of NBD-labeled peptides to cells. NBDN36, C16-N36MNBD, and NBDN36M-C16 are represented by closed squares,
closed triangles, and open triangles, respectively. For comparison, a non-binding peptide NBDGCN4 (open circles) and the strongly binding peptide
C16-NBDGCN4 (closed circles) were measured.
doi:10.1371/journal.ppat.1000509.g003
Table 2. Sequences and designations of the NBD labeled peptides and their lipophilic conjugates.
Designation X Peptide sequence Z
NBDN36 NBD X- SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL
NBDN36M-C16 NBD X- SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILK(d-NHZ)- C 1 6
C16-N36MNBD C16- X- SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILK(d-NHZ) NBD
NBDGCN4 NBD X- KQIEDKIEEILSKIYHIENEIARIKKLIGER
C16-NBDGCN4 C16- X-K ( d-NHZ)QIEDKIEEILSKIYHIENEIARIKKLIGER NBD
doi:10.1371/journal.ppat.1000509.t002
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and measured by FACS. Further analysis, as specified in the
Materials and Methods section, enabled us to compare the relative
level of the peptide’s binding for each cell population (Figure 6).
The NBDGCN4 peptide served as a negative control for a non-
binding peptide, whereas C16-NBDGCN4 served as a positive
control for a strongly binding peptide without preference for a
specific cell population. A line is drawn in each panel to emphasize
where we would expect the data in case there is no preference
among the different populations. Since the NBDGCN4 peptide
does not bind the membranes, all the data points are concentrated
in the lower left-hand corner. We can conclude that (in the same
conditions as for the experiments determining the inhibitory
activity of the peptides) there is a tendency of the conjugated N36
peptides to reside more on target than on effector cells.
Discussion
Using synthetic peptides with homologous sequences to
endogenous domains within gp41 is a powerful tool to decipher
the molecular mechanism of HIV-cell fusion. Among these
peptides the NHR and CHR play a crucial role. Studies with
Figure 4. CD spectroscopy of the peptides alone, and together with C34. The peptides were measured at 10 mM in HEPES buffer (5 mM,
pH 7.4) or 1% LPC in H2O (membrane mimetic environment). Left column: The peptide signal alone in buffer solution (open circles) compared to the
peptide signal in 1% LPC (closed circles). Middle column: The calculated, non-interacting signal for the N-peptide with C34 (open triangles), compared
to the observed experimental signals, obtained following incubation of the two peptides together in buffer solution (closed triangles). Right column:
The same experiment was done in LPC. The calculated non-interacting and the experimental signals are represented by open and closed squares,
respectively.
doi:10.1371/journal.ppat.1000509.g004
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which gp41 adopts an extended conformation in the pre-fusion
step, inserts the fusion peptide into the target membrane while
the NHR forms a trimeric coil-coiled structure. A critical step
toward membrane fusion is the collapse of this structure to form
the SHB. CHR-derived synthetic peptides can prevent SHB
formation by competing with the endogenous CHR domain for
the binding of the NHR trimers (Figure 7). For such an
inhibition to occur, CHR needs to bind in an antiparallel
manner to the NHR. To support this mechanism, we have
previously anchored short CHR peptides to the cell membrane
by palmitic acid conjugation. The CHR derived lipopeptides
had 30-fold higher inhibitory activity when attached via their C-
terminus (antiparallel to the endogenous NHR), compared to the
N-terminus. That study also demonstrated the C-terminal
boundary of the six helix bundle [22].
Figure 5. Cell-cell fusion inhibition assay for the N36 mutants as well as their fatty acid conjugates. (A) Fusion inhibition induced by the
N36 MUTe,g peptides. The IC50 values of the different peptides are presented. For each peptide at least four independent experiments were
performed and were included in the calculation of the standard deviation. (B) The inhibitory oligomeric state of the peptides. The Hill’s coefficient
parameter for the different peptides is presented. For each peptide at least four independent experiments were performed and were included in the
calculation of the standard deviation.
doi:10.1371/journal.ppat.1000509.g005
Table 3. Sequences, designations, and IC50 values of the N36 mutated peptides and their lipophilic conjugates.
Designation X Peptide sequence ZI C 50(nM)
N36 MUTe,g H X- SGIDQEQNNLTRLIEAQIHELQLTQWKIKQLLARILK 936636
C16-N36 MUTe,g C16- X- SGIDQEQNNLTRLIEAQIHELQLTQWKIKQLLARILK 16264
N36 MUTe,g-C16 H X- SGIDQEQNNLTRLIEAQIHELQLTQWKIKQLLARILK(d-NHZ) -C16 8.864
N36 MUTa,d H X- SGIVQQLNNQLRAEEANQHLEQLSVWGSKQNQARRLK inactive
C16-N36 MUTa,d C16- X- SGIVQQLNNQLRAEEANQHLEQLSVWGSKQNQARRLK inactive
N36 MUTa,d-C16 H X- SGIVQQLNNQLRAEEANQHLEQLSVWGSKQNQARRLK(d-NHZ) -C16 inactive
doi:10.1371/journal.ppat.1000509.t003
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NHR peptides display a distinct feature in comparison to the
CHR peptides in their ability to self oligomerize in solution
[34,35]. Thus, they can bind to two endogenous domains of gp41
in the pre-fusion extended conformation [20]. Synthetic NHR can
bind the endogenous NHR to prevent the formation of the coil-
coiled NHR trimer probably as dimers or as monomers (Figure 7).
In addition, NHR can bind the CHR and hence prevent
endogenous SHB core formation (Figure 7). Binding to the
CHR region depends on the ability of the NHR to homo-
oligomerize [20], probably as a trimer. In support of this,
enhancing the trimeric tendency of N36 increases its inhibitory
Figure 6. Relative binding of labeled peptides to the membrane of specific cell populations. In each panel the Y axis represents the
percentage of target cells (with receptors) labeled with NBD-peptide whereas the X axis represents the percentage of effector cells (with envelope
glycoprotein) labeled with NBD-peptide. The lower panels illustrate two controls utilized: NBDGCN4 as a non-binding peptide and C16-NBDGCN4 as a
strongly non-specific binding peptide. A line is drawn in each panel to emphasize where we would expect the data in case there is no preference
between the different populations. The different data points represent rising peptide concentrations.
doi:10.1371/journal.ppat.1000509.g006
Figure 7. A cartoon illustrating possible modes of inhibition. The NHR region is denoted by green cylinders, the CHR region is denoted by
orange cylinders, and the fusion peptide is denoted by a black line. The C-terminus of the inhibitory N- or C-peptides is represented by a black color.
The Pre-fusion conformation is presented on the left of the middle panel. N36 can bind the Pre-fusion conformation in two ways: It can bind the CHR
region and inhibit progression into the Post-fusion conformation, or it can interrupt the creation of the central NHR coiled-coil by driving the
equilibrium towards the dimeric and monomeric forms (here only the monomeric form is presented for simplicity) thereby preventing progression
into the Post-fusion conformation. CHR can only bind the NHR region in the Pre-fusion conformation thereby preventing fusion.
doi:10.1371/journal.ppat.1000509.g007
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is primarily responsible for binding of the CHR region. In both of
these mechanisms the directionality of the NHR towards the
internal pre-fusion conformation seems to be important. To test
this hypothesis we conjugated fatty acids with increasing lengths to
the N or C-terminus of N36, and the inhibitory activity of the
resulting lipopetides was examined in a cell-cell fusion assay.
Importantly, the IC50 of the resulting lipopeptides increased
significantly in correlation to the length of the fatty acid (Figure 1),
as well as to their ability to bind cells which was examined by a
triple staining assay (Figure 3). However, in contrast with the
CHR, we found that the directionality of the attachment of N36
was not critical, since the attachment of the same fatty acid to N36
increased its inhibitory activity similarly, independent of whether it
was attached to the C- or N-terminus (Figure 1). These findings
suggest a planary orientation of the endogenous NHR region, as
well as the N36 lipopeptides, on the cell membrane. Indeed,
previous studies have revealed that NHR derived peptides can
bind and assemble on a membrane and adopt an a-helical
structure [38,39,40,41,42,43]. Since it is less likely that internal
coiled-coil will disassemble after its creation, we suggest that a
loose extended conformation is created after the conformational
changes induced by the receptors and co-receptors binding. In this
conformation the FP is inserted into the host cell membrane but
the internal coiled-coil is not formed yet (‘‘loose’’ Pre-fusion in
Figure 8). Then, the NHR coiled-coil is formed which leads to its
parallel orientation towards the membrane, and finally folding into
the post-fusion conformation. In this model the peptides with the
long fatty acid will create a chimeric coiled-coil with endogenous
NHR leading to an altered sequence of events as is presented in
Figure 8 at the bottom. However, it is possible that the conjugated
peptides inhibit partially also from solution. We suggest that these
gp41 conformations: the loose pre-fusion conformation and the
NHR region lying parallel to the cell membrane, are additional
intermediate conformations during the fusion process.
We observed two different shapes of the inhibition curves of
N36 and its fatty acid derivatives: sigmoid for the N36 and short
fatty acids conjugated peptides, in contrary to hyperbolic for the
longer fatty acid conjugates (see Figure 2A). We utilized a
derivative of Hills’ equation for the fitting of the experimental cell-
cell fusion assay data, and for extracting the IC50 value, in which
the Hill coefficient represents the oligomeric tendency of the
peptide in the inhibition process. Examining the oligomeric
parameters revealed an interesting trend. The soluble unmodified
N36 and N36M peptides act as trimers, whereas the strongly
membrane bound lipopeptides C16-N36 and N36M-C16 act as
monomers (see Figure 2B). We speculated that N36 mostly binds
the CHR as a trimer (However, the monomeric fraction of these
peptides can also bind the endogenous NHR) while C16-N36
mainly binds the endogenous NHR as monomers.
To further support this, we conjugated palmitic acid to the N-
or C-terminus of two previously studied N36 mutants: (i) N36
Figure 8. A cartoon illustrating a plausible model for the fusion process and its inhibition by the long fatty acid conjugated
peptides. The NHR region is denoted by green cylinders, the CHR region is denoted by orange cylinders, the inhibitory N36 peptide is denoted by
blue cylinders (blue and black for the N- and C-terminal of the peptide, respectively), and the fatty acid is denoted by a thick black line. On the left is
the conformation immediately after the binding of the receptors and co-receptors, in which the NHR coiled-coil has not been created yet- ‘‘loose’’
pre-fusion. If the NHR region, as well as the N36 peptide, has a planar orientation towards the cell membrane, it can explain the directionality
independence of fatty acid conjugation. Here, we show only the interference with the formation of the trimeric coiled-coil since it appears to be the
main inhibitory mode of the conjugated N36 peptides.
doi:10.1371/journal.ppat.1000509.g008
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in its inability to interact with the CHR, and (ii) N36 MUTa,d
which contains mutations in it’s a and d positions knocking out its
ability to interact with itself, leading to inability to create the
internal coiled-coil [20]. Fatty acid conjugation to N36 MUTa,d
could not compensate for the inhibitory obligatory requirement of
N36 self binding. In contrast, fatty acid conjugation dramatically
increased the inhibitory activity of N36 MUTe,g (up to 100-fold).
In this case the C-terminal anchored N36 MUTe,g-C-16 is about
20-fold more active than the N-terminal anchored C-16-N36
MUTe,g. Importantly, N36 MUTe,g, C16-N36 MUTe,g, and N36
MUTe,g can bind the NHR but not the CHR. The fitting of their
inhibitory curves reveal that they bind the endogenous NHR
region in a monomeric form (Figure 5B).
The enhanced inhibitory activity of the conjugated peptides can
be accounted for by: (i) increased local concentration of the
conjugated peptides on the membrane surface resulting in
increased accessibility near the fusion site. (ii) If conjugation of a
fatty acid indeed changes the tendency of the peptide into a
monomeric inhibitory mode of action, then less peptides are
required to exert the same inhibitory effect thus reducing the IC50
value, and (iii) When N36 inhibits it can bind simultaneously to the
NHR and CHR regions of the same pre-fusion structure. In
contrast, when a peptide can only bind one target site (like N36
MUTe,g or the monomeric conjugated peptides) a lower
concentration exerts the same effect thus reducing the IC50 value.
Interestingly, analysis of the inhibitory curves of C-helix peptides
also reveal, as expected, a monomeric mode of action (data not
shown). Since, similarly to the anchored N36 MUTe,g, a C-helix
peptide can bind only the NHR, the inhibitory activities of N36
MUTe,g-C16 and e.g. T-20 are similar and in the low nanomolar
range.
Combining these results it seems that N36, N36M or the
lipopeptides with the short fatty acids primarily target the
endogenous CHR region as trimers, and that conjugation of a
long fatty acid leads to a shift toward a lower oligomerization
requirement for the inhibition reaction, thereby primarily
targeting the endogenous NHR region. Apparently, the mem-
brane bound peptide does not depend on trimerization for the
inhibition activity similarly to the N36 peptide in solution;
membrane binding compensates for the trimerization require-
ment. Strengthening this assumption is another interesting finding
- a tendency of the N36 conjugates to reside more on the target
cells that occupy the receptors than on the effector cells (Figure 5).
This feature was detected by a triple staining assay performed
under the same protocol conditions utilized for the cell-cell fusion
assay.
A new anti-HIV-1 therapeutic category classified as fusion
inhibitors emerged to the HAART (Highly Active Antiretroviral
Therapy) with the entry of a C-peptide named enfuvirtide. The
potential of C- and N-peptides to inhibit the fusion process of the
virus was discovered simultaneously. Nevertheless, most efforts
were aimed at developing C-peptides as drugs. This was due to
inferior inhibitory activities demonstrated by N-peptides, which
were attributed to their tendency to form weakly active oligomers.
Studies that have demonstrated improved inhibition of N-peptides
are rare and include (i) Stabilization of a specific, usually a
trimeric, coiled-coil NHR complex, by fusion to unrelated coiled-
coils [36], by covalently connecting NHR regions [37,44,45], or by
combining different methods including point mutations in specific
heptad repeat positions [17]. (ii) Creation of an incomplete core
complex [46]. (iii) Abolishing the CHR binding capability by
altering the e and g positions of the N36 heptad repeat [20],
resulting in enhanced inhibition, probably due to reduced
aggregation. Most of these methods involve elaborate techniques.
Here we have demonstrated a significantly enhanced inhibitory
activity of an N-peptide by a simple chemical reaction that
involves the attachment of a fatty acid to N36. The similarity
between functional regions in the envelopes of many viruses
suggests a possible new therapeutic approach.
In summary, taking all of the results into consideration leads us
to suggest that our peptides demonstrate a shift in the inhibitory
mode of action from mainly a trimeric, oligomeric N36/N36M
complex, which can target either the internal NHR coiled-coil or
the CHR region, to monomeric lipopetides that mostly target the
internal NHR coiled-coil. Additionally, the similar inhibitory effect
of the N- and C-terminally conjugated peptides suggests that the
mode of inhibition involves a planary peptide orientation on the
membrane’s surface indicating a possible additional intermediate
conformation during the fusion process. (Figure 8). Importantly,
this study demonstrates that a simple chemical conjugation of fatty
acids to N36 can significantly increase its inhibitory activity.
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